Clinical Endocannabinoid Deficiency and Cognitive Continuity: A Longitudinal Case Study Challenging the Neurodegeneration Paradigm
Department of Research, Publication, & Education, AMCANN, LLLP (Independent Research Organization), Murrieta, California, USA.
Research Article
World Journal of Biological and Pharmaceutical Research, 2025, 09(02), 020-033.
Article DOI: 10.53346/wjbpr.2025.9.2.0025
Publication history:
Received on 18 November 2025; revised on 23 December 2025; accepted on 26 December 2025
Abstract:
Despite expanding acceptance of cannabis for medicinal use, empirical literature remains sparse regarding the long-term mental and neurobiological outcomes of continuous cannabis exposure over several decades. This self-case study examines the psychobiological trajectory of a biomolecular psychologist who has used cannabis intermittently since the 1970s and therapeutically since 2010 to manage polypharmacy withdrawal, opioid dependence, and psychiatric symptoms. The analysis integrates self-observational data, neurocognitive assessments, pharmacological history, and psychosocial context to evaluate outcomes on affect regulation, cognitive performance, neuroplasticity, and motivation. The case challenges persistent assumptions of irreversible cannabis-induced cognitive decline and supports the hypothesis that sustained cannabinoid modulation may promote neural resilience when employed within a biomolecularly informed framework. Findings are illustrative and intended to generate testable hypotheses rather than establish causality.
Keywords:
Endocannabinoid system; Cannabinoids; Psychoneuroimmunology; Neuroadaptive Resilience; Longitudinal Case Study; Clinical Endocannabinoid Deficiency (CECD); Cannabinoid Homeostasis
Full text article in PDF:
Copyright information:
Copyright © 2025 Author(s) retain the copyright of this article. This article is published under the terms of the Creative Commons Attribution Liscense 4.0